西非裔去势抵抗性前列腺癌患者来源异种移植模型的表征
本研究建立了一例来自估计90%西非血统的转移性去势抵抗性前列腺癌患者的患者来源异种移植模型(PCPDX),并对其病理、核型、突变、拷贝数、基因融合、表达、生长速率、治疗反应及实验性转移进行了表征。该模型具有TP53突变及PTEN和RB1缺失,冻存复苏后小鼠接种成功率100%,表现为去势和 docetaxel 耐药、cisplatin 敏感,尾静脉注射后可定植小鼠肺部。该模型可用于临床前研究前列腺癌生物学异质性及测试新疗法。
要点
- 建立西非裔转移性去势抵抗性前列腺癌PCPDX,具TP53突变及PTEN、RB1缺失。
- 该PCPDX冻存复苏后小鼠接种成功率100%,去势和docetaxel耐药、cisplatin敏感。
- 尾静脉注射后PCPDX肿瘤细胞可定植小鼠肺部,可用于临床前转移研究。
核心结论
- 该PCPDX与其它已建立表征的模型一起,将有助于临床前研究前列腺癌生物学异质性并测试新疗法。
研究设计与样本
- 本研究建立了一例来自估计90%西非血统的转移性去势抵抗性前列腺癌患者的PCPDX,并对其病理、核型、热点突变、拷贝数、基因融合、基因表达、正常及去势小鼠中的生长速率、治疗反应和实验性转移进行了表征。
主要发现
- 该PCPDX具有TP53突变以及PTEN和RB1缺失。
- 冻存复苏后小鼠接种成功率为100%。
- 该PCPDX对去势和docetaxel耐药、对cisplatin敏感,并具有与这些药物反应相关的基因表达模式。
- 尾静脉注射后,PCPDX肿瘤细胞可定植小鼠肺部。
临床怎么用
- 该PCPDX可用于临床前研究前列腺癌生物学异质性及测试新疗法,尤其可能反映西非裔去势抵抗性前列腺癌的临床特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficult to establish because of limited specimen availability and poor uptake rates in immunodeficient mice. Ancestrally diverse PCPDXs are even more rare, and only six PCPDXs from self-identified African American patients from one institution were recently made available. METHODS: In the present study, we established a PCPDX from prostate cancer tissue from a patient of estimated 90% West African ancestry with metastatic castration resistant disease, and characterized this model's pathology, karyotype, hotspot mutations, copy number, gene fusions, gene expression, growth rate in normal and castrated mice, therapeutic response, and experimental metastasis. RESULTS: This PCPDX has a mutation in TP53 and loss of PTEN and RB1. We have documented a 100% take rate in mice after thawing the PCPDX tumor from frozen stock. The PCPDX is castrate- and docetaxel-resistant and cisplatin-sensitive, and has gene expression patterns associated with such drug responses. After tail vein injection, the PCPDX tumor cells can colonize the lungs of mice. CONCLUSION: This PCPDX, along with others that are established and characterized, will be useful pre-clinically for studying the heterogeneity of prostate cancer biology and testing new therapeutics in models expected to be reflective of the clinical setting.
引用
- Patierno BM, Foo WC, Allen T, et al. Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer Prostatic Dis. 2021. PMID: 34645983. doi:10.1038/s41391-021-00460-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。